MedTrace Logo

Early Detection of Breast Cancer

NCT06043661 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2023-09-21

No results posted yet for this study

Summary

The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer. The TriNetra™Breast test should be a useful breast cancer screening option for asymptomatic women 40 years of age and older.

This pivotal study is designed to provide evidence of test performance and to demonstrate its safety in the intended use population in the USA.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

  • Datar Cancer Genetics Inc

    lead INDUSTRY

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043661 on ClinicalTrials.gov